<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571919</url>
  </required_header>
  <id_info>
    <org_study_id>44300</org_study_id>
    <nct_id>NCT03571919</nct_id>
  </id_info>
  <brief_title>Lidocaine Infusions for Rib Fractures</brief_title>
  <acronym>Lidocare</acronym>
  <official_title>Efficacy of Intravenous Lidocaine Infusion for Traumatic Rib Fracture Pain Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Lin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with traumatic rib fractures not receiving regional anesthesia through a epidural or
      nerve block catheter will be recruited for the study. Once enrolled, they will be randomized
      to receive either intravenous lidocaine or intravenous saline for control of pain related to
      their rib fractures. In addition, they will receive other pain medications, such as
      acetaminophen, gabapentin, and opioid pain medications. Our primary outcome is a decrease in
      their opioid medication requirements.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Immediate care providers (nurses, primary teams) will be blinded; however, lidocaine levels will be monitored by the acute pain service, a consulting team providing direct care to the patient, who will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid pain medicine usage</measure>
    <time_frame>Average per 24 hours</time_frame>
    <description>Total opioid pain medicine usage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCA requirements</measure>
    <time_frame>5 days</time_frame>
    <description>Percentage of patients requiring PCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>5 days</time_frame>
    <description>Average pain scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>5 days</time_frame>
    <description>Average length of stay in ICU and hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory failure</measure>
    <time_frame>5 days</time_frame>
    <description>Rates of pneumonia or other respiratory failure (pneumonia defined as (1) new pulmonary infiltrate on chest X-ray and (2) two of three of the following: (a) productive cough (b) WBC &gt; 12,000 and (c) temperature &gt; 38.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Mortality rate between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility</measure>
    <time_frame>2 days</time_frame>
    <description>Highest level of mobility on hospital day #2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Rib Fracture Multiple</condition>
  <condition>Trauma Chest</condition>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive normal saline bolus and infusion and have sham lab draws every 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive lidocaine bolus and infusion and have lidocaine lab draws every 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine infusion</intervention_name>
    <description>Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline infusion</intervention_name>
    <description>Intravenous bolus of saline and then infusion</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged 18 or older with 2+ rib fractures or &gt; 65 with 2+ rib fractures Enrollment
        within 16 hours of admission Inability to receive epidural placement or other
        catheter-based regional anesthesia (coagulopathy, anticoagulation, bacteremia or infection
        over epidural site, patient refusal, vertebral fracture, spinal cord injury, inability to
        cooperate with procedure, BMI &gt; 40) Isolated rib fracture (no other major injury or
        anticipation for invasive procedure)

        Exclusion Criteria:

        Inability to participate in traditional pain measures Severe alcohol withdrawal Chronic
        pain requiring opiates prior to admission GCS &lt; 13 or inability to report pain Medical
        instability Positive pressure ventilation, either via non-invasive mask or endotracheal
        tube Hemodynamic instability or shock Flail chest with clinical evidence of paradoxical rib
        motion Contraindication to lidocaine History of or current bradycardia (HR &lt; 50) or heart
        block (Mobitz II or 3rd degree) New onset or uncontrolled seizures Allergy to amide-type
        local anesthetic

        Enrollment in other study that may affect the results of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Y Lin, MD</last_name>
    <phone>4158431186</phone>
    <email>mikelin@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shikha Kapil, MD</last_name>
    <email>skapil@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Y Lin, MD</last_name>
      <phone>415-843-1186</phone>
      <email>michaelylin@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>June 27, 2018</last_update_submitted>
  <last_update_submitted_qc>June 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Michael Lin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Lidocaine infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Rib Fractures</mesh_term>
    <mesh_term>Fractures, Multiple</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

